Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma

References

• Osgood E. “The survival time of patients with plasmacytic myeloma”. Cancer Chemotherapy Reports 1960; 9: 1–10
   PubMedGoogle Scholar
• Alexanian R., Bonnet J., Gehan E., Haut A., Hewlett J., Lane M., Monto R., Wilson H. “Combination chemotherapy for multiple myeloma”. Cancer 1972; 30: 382–389
   PubMed Web of Science ®Google Scholar
• Gregory W., Richards M., Malpas J. “Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials”. Journal of Clinical Oncology 1992; 10: 334–342
   PubMed Web of Science ®Google Scholar
• Myeloma Trialists' Collaborative Group. “Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials”. Journal of Clinical Oncology 1998; 16: 3822–3842
   PubMed Web of Science ®Google Scholar
• For the Myeloma Trialists' Collaborative Group (MTCG), Wheatley K. “The role of interferon (IFN) as therapy for multiple myeloma: an overview of 24 randomized trials with over 4000 patients”. Proceedings of the American Society of Clinical Oncology 1998; 17: 8a
   Google Scholar
• Attal M., Harousseau J.-L., Stoppa A.-M., Sotto J.-J., Fuzibet J.-G., Rossi J.-F., Casassus P., Maisonneuve H., Facon T., Ifrah N., Payen C., Bataille R. “A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma”. New England Journal of Medicine 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Durie B., Salmon S. “A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival”. Cancer 1975; 36: 842–854
   PubMed Web of Science ®Google Scholar
• Uyl-de Groot C., Ossenkoppele G., van Riet A., Rutten F. “The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma”. European Journal of Cancer 1994; 30A: 457–459
   PubMed Web of Science ®Google Scholar
• Duncan N., Hewetson M., Powles R., Raje N., Mehta J. “An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma”. Bone Marrow Transplantation 1996; 18: 1175–1178
   PubMed Web of Science ®Google Scholar
• Jagannath S., Vesole D. H., Zhang M., Desikan K. R., Copeland N., Jagannath M., Bracy D., Jones R., Crowley J., Tricot G., Barlogie B. “Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma”. Bone Marrow Transplantation 1997; 20: 445–450
   PubMed Web of Science ®Google Scholar
• Henon P., Donatini B., Eisenmann J. C., Becker M., Beck-Wirth G. “Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma”. Bone Marrow Transplantation 1995; 16: 19–25
   PubMed Web of Science ®Google Scholar
• Trippoli S., Messori A., Becagli P., Alternini R., Tendi E. “Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation”. Oncology Reports 1998; 5: 1475–1482
   PubMed Web of Science ®Google Scholar
• Sampson F., Beard S., Scott F., Vandenberghe E. “Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma”. British Journal of Haematology 2001; 113: 1015–1019
   PubMed Web of Science ®Google Scholar
• Browman G., Bergsagel D., Sicheri D., O'Reilly S., Wilson K., Rubin S., Belch A., Shustik C., Barr R., Walker I., James K., Zee B., Johnston D. “Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group”. Journal of Clinical Oncology 1995; 13: 2354–2360
   PubMed Web of Science ®Google Scholar
• Barlogie B., Smith L., Alexanian R. “Effective treatment of advanced multiple myeloma refractory to alkylating agents”. New England Journal of Medicine 1984; 310: 1353–1356
   PubMed Web of Science ®Google Scholar
• Norman G., Streiner D. Biostatistics the Bare Essentials. B.C. Decker, Hamilton, Ontario 1998
   Google Scholar
• Statistics Canada CANSIM. Consumer price index, 1996 classification, annual average indexes, Canada and provinces. Ottawa 2000
   Google Scholar
• Ministry of Health and Long-Term Care. Ontario Drug Benefit Formulary. 2001; 37
   Google Scholar
• Ontario Ministry of Health and Long-Term Care. Schedule of Benefits. Physician Services Under the Health Insurance Act. 2000
   Google Scholar
• Ortega A., Dranitsaris G., Puodziunas A. “A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapy”. International Journal of Technology Assessment in Health Care 1998; 14: 788–798
   PubMed Web of Science ®Google Scholar
• The Canadian Cost of Transfusion Study Group, Tretiak R., Laupacis A., Rivière M., McKerracher K., Souetre E. “Cost of allogeneic and autologous blood transfusion in Canada”. Canadian Medical Association Journal 1996; 154: 1501–1508
   Web of Science ®Google Scholar
• Kaplan E., Meier P. “Nonparametric estimation from incomplete observations”. Journal of the American Statistical Association 1958; 53: 457–485
   Web of Science ®Google Scholar
• Fleiss J. Statistical Methods for Rates and Proportions. John Wiley, New York 1973
   Google Scholar
• Fisher R. Statistical Methods for Research Workers. Hafner Press, New York 1970
   Google Scholar
• Mantel N. “Evaluation of survival data and two new rank order statistics arising in its consideration”. Cancer Chemotherapy Reports 1966; 50: 163–170
   PubMedGoogle Scholar
• Viscusi W. “Discounting health effects for medical decisions”. Valuing Health Care: Costs, Benefits and Effectiveness of Pharmaceuticals and Medical Technologies, F. Sloan. Cambridge University Press, New York 1995; 123–145
   Google Scholar
• Donatini B., Henon P., Becker M. “Peripheral blood stem cell transplantation in multiple myeloma. Clinical benefits and cost analysis”. British Journal of Medical Economics 1994; 7: 55–62
   Google Scholar
• Kukull W., Koepsell T., Conrad D. “Rapid estimation of hospitalization charges from a brief medical record review: evaluation of multivariate prediction model”. Medical Care 1986; 24: 961–966
   PubMed Web of Science ®Google Scholar
• Bulpitt C., Fletcher A. “The measurement of quality of life in hypertensive patients: a practical approach”. British Journal of Clinical Pharmacology 1990; 30: 353–364
   PubMed Web of Science ®Google Scholar
• How do the outcomes of patients treated within randomised control trials compare with those of similar patients treated outside these trials?. 2000, http://hiru.mcmaster.ca/edm/trout/
   Google Scholar
• Smith T., Hillner B., Desch C. “Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis”. Journal of the National Cancer Institute 1993; 85: 1460–1474
   PubMed Web of Science ®Google Scholar
• Laupacis A., Feeny D., Detsky A., Tugwell P. “How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations”. Canadian Medical Association Journal 1992; 146: 473–481
   PubMed Web of Science ®Google Scholar